As of February 2026, the global healthcare sector is witnessing a decisive pivot in the management of chronic refractory conditions, with the Neuropathic Pain Market emerging as a primary sector for bio-electronic and pharmacological convergence. The increasing incidence of peripheral nerve damage—secondary to metabolic disorders and traumatic injury—has necessitated a...